In the Media: Pure, micronized salt has an effect on respiratory viruses – including COVID-19
Danish and Brazilian researchers conducted a study on the effects of salt (NaCl) on respiratory viruses, including COVID-19. They found...
top of page
Dry NaCl powder inhaler
BREATHOX® is a dry NaCl powder inhaler containing micronized NaCl inhalable size ; 1-10 μm
The worlds only...
BREATHOX® is the worlds only medical device that dispense a metered dose of NaCl particles into the upper and lower airways
Cleaning airways
BREATHOX ® promotes the cleaning of the airways and relieves respiratory tract irritation and mucus accumulation
Natural Self-care Product
BREATHOX® supports the growing trend of natural therapies and self-care treatment in the consumer healtcare market
We aspire...
to make the world a better place – to breathe
For chronic patients, such as:
-
COPD patients
-
Cystic Fibrosis patients
-
Asthma patients
For temporary patients, such as:
-
Common Cold patients
-
Covid-19 patients
-
Pollution victims
-
Smokers
Products
-
Dry/Wet Salt
-
Nasal/Oral
Indications
-
Antiviral
-
Anti-inflammatory
-
Pediatric
Latest News
Catch up on the latest news & updates here
05 September 2022 • Press Release
New Scientific Discovery Points Toward a Natural Solution for Mild to Moderate Covid-19 Patients
We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.
“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”
“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).
02 September 2022 • Media Update
LIITA Research to be Presented at ERS Congress 2022
We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.
“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”
“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).
Come join us Monday the 5th of September at 12.45 pm (Room 8L).
2022 • News Article
Stay tuned for more news
TBA
Latest News
Catch up on the latest news & updates here
Latest News
Catch up on the latest news & updates here
bottom of page